Published and registered-study descriptions of ibogaine use can look precise while representing very different settings, formulations, screening practices, and monitoring standards. This page compares what is reported without turning those reports into a dosing recommendation.
Literature commonly distinguishes between larger, acute administrations described for interruption-oriented treatment, and lower or repeated administrations often described as microdosing or maintenance. The categories are not standardized, and reports sometimes use the same words for materially different practices.
Ibogaine is generally discussed as a psychoactive indole alkaloid derived from Tabernanthe iboga. Reported route, formulation, participant selection, co-occurring substance use, and follow-up can all affect how a protocol should be read.
For broader context on administration pathways and safeguards, the independent administration overview situates dose reporting alongside setting and monitoring rather than treating milligrams as a stand-alone decision.
Review safety and monitoring contextThe table summarizes patterns described in observational accounts and trial materials. Ranges are approximate reporting conventions, not medical guidance, and evidence is limited or inconsistent across uses.
| Reported purpose | Reported amount pattern | Frequency and route | Onset and duration notes | Documented safety flags |
|---|---|---|---|---|
| Addiction interruption | Often described as a single weight-based oral administration, sometimes called a “flood” dose; published accounts vary substantially. | Usually one acute session in reported programs, occasionally preceded or followed by smaller amounts. Oral capsules or plant-derived preparations are most often described. | Effects are commonly reported over many hours, with prolonged after-effects and a metabolite that may persist longer than the initial experience. | QT prolongation, arrhythmia risk, vomiting, dehydration, interactions, withdrawal-related complications, and risk from inadequate screening or emergency response. |
| Microdosing | Lower repeated amounts are described, but no generally accepted dose range or protocol definition exists in clinical guidance. | Repeated oral use is often described in informal settings. Frequency varies widely and may be intermittent or consecutive. | Pharmacokinetic data are insufficient to make broad comparisons across products or schedules; accumulation and interaction questions remain relevant. | Lower reported amounts do not remove cardiac risk or medication-interaction concerns. Evidence for benefits and safety is limited. |
| Maintenance or staged use | Some accounts describe smaller follow-on or split administrations after an acute session; published approaches are heterogeneous. | May be split over time, but schedules are not standardized and are not interchangeable with trial protocols. | Timing may overlap with ongoing physiological effects or noribogaine exposure, complicating simple “one dose” comparisons. | Repeated exposure may extend the period in which monitoring, medication review, and cardiac caution matter. |
A stated dose is incomplete without the product and route. Research descriptions may refer to purified ibogaine hydrochloride, total alkaloid extracts, root-bark preparations, or other materials with different composition and uncertainty.
Research and registered-trial contexts may specify a purified formulation and a weight-based oral amount. Such protocols generally include eligibility criteria and observation that cannot be inferred from the dose number itself.
Descriptions involving root bark, teas, or total alkaloid extracts may not provide reliable equivalence to purified material. Batch variability makes cross-study comparison especially uncertain.
Some reports divide amounts across time or describe subsequent lower administrations. The available literature does not support treating these as settled, transferable schedules.
Published pharmacology identifies ibogaine and noribogaine as distinct compounds with differing time courses; a dose comparison therefore should not assume that the end of an acute experience is the end of relevant exposure. The PubChem record for ibogaine provides a technical compound reference, while clinical meaning still depends on the study or setting.
Accounts of where these practices are offered also differ substantially. A comparison of reported Mexico-based ibogaine settings may help readers distinguish location claims from evidence about a particular protocol.
The central limitation of dose comparison is safety: risk cannot be reduced to one threshold. It may be shaped by cardiac history, electrolyte status, other medications or substances, product uncertainty, and the capacity to respond to an emergency.
Ibogaine has been associated with QT interval prolongation and potentially serious rhythm disturbances. The U.S. Food and Drug Administration’s discussion of QT-related arrhythmia risk illustrates why medication and electrolyte context matters when a substance can affect cardiac repolarization.
Reports frequently describe a long acute period and lingering effects. A shorter or split administration description does not, by itself, establish a shorter monitoring need or eliminate potential interactions.
“Flood,” “microdose,” and “maintenance” are descriptive labels rather than universally defined clinical categories. Product identity, screening, observation, and co-use details often determine whether two reports are meaningfully comparable.
In the United States, ibogaine is listed as a Schedule I controlled substance under the DEA drug scheduling framework. Trial descriptions and informal reports should not be mistaken for approved treatment instructions.
Questions about outcomes are separate from questions about dose. The plain-language overview of what ibogaine is reported to do can help keep claimed effects distinct from safety evidence and protocol details.
“A reported range is a description of what happened in a particular context, not a recipe for reproducing it.”
Registered studies can be useful for locating stated eligibility criteria, formulation details, and outcome measures, but a trial listing does not itself establish effectiveness or general safety. Readers can inspect how studies are described through ClinicalTrials.gov study records and note whether a result has been published.
Evidence summaries may also combine small trials, observational programs, and case reports with different methods. The National Institute on Drug Abuse overview of medications for opioid use disorder is useful context for distinguishing established, regulated treatment options from experimental or unapproved approaches.
When assessing a facility description, the details that matter are not only an advertised dose but also medical evaluation, medication reconciliation, cardiac planning, monitoring, and emergency capability. The discussion of treatment-facility considerations keeps those questions in view.
This resource does not recommend a dose, route, schedule, or provider. Evidence changes, and individual risk assessment belongs with qualified, appropriately licensed care.
For readers considering availability claims in the United States, the overview of ibogaine’s U.S. context adds regulatory and setting questions that a dose chart cannot answer.